Clinical trial • Phase I • Oncology
DSB2455 for Breast cancer | Ovarian cancer | Metastatic castration-resistant prostate cancer | Brain metastases
Phase I trial of DSB2455 for Breast cancer | Ovarian cancer | Metastatic castration-resistant prostate cancer | Brain metastases.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Breast cancer | Ovarian cancer | Metastatic castration-resistant prostate cancer | Brain metastases
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 14-06-2024
- First CTIS Authorization Date
- 23-09-2024
Trial design
None/Not specified-controlled Phase I trial across 19 sites in Spain, France, Hungary and others.
- Comparator
- None/Not specified
- Biomarker Stratified
- True, BRCA1/2 and HRR alterations
- Target Sample Size
- 101
Recruitment
- Planned Sample Size
- 101
- Recruitment Window Months
- 32
Geography
- Total Number Of Sites
- 19
- Total Number Of Participants
- 101
Spain
- Earliest CTIS Part Ii Submission Date
- 01-08-2024
- Latest Decision Or Authorization Date
- 13-05-2026
- Processing Time Days
- 650
- Number Of Sites
- 11
- Number Of Participants
- 60
Sites
- Site Name
- Hospital Universitario Virgen De La Victoria
- Department Name
- Oncology
- Contact Person Name
- Marcos Iglesias Campos
- Contact Person Email
- marcos.iglesias@ibima.eu
- Site Name
- Fundacion Instituto Valenciano De Oncologia
- Department Name
- Oncology
- Contact Person Name
- David Lorente Estelles
- Contact Person Email
- dlorente@fivo.org
- Site Name
- Hospital Universitario Reina Sofia
- Department Name
- Oncology
- Contact Person Name
- Rosa María Rodríguez Alonso
- Contact Person Email
- rosarodriguezalonso@gmail.com
- Site Name
- Hospital Hm Nou Delfos
- Department Name
- Oncology START Barcelona – HM Nou Delfos
- Contact Person Name
- Tatiana Hernández Guerrero
- Contact Person Email
- Tatiana.hernandez@start-barcelona.com
- Site Name
- Hospital Universitario Hm Sanchinarro
- Department Name
- Oncology
- Contact Person Name
- Ramón Yarza Barrio
- Contact Person Email
- ramon.yarza@startmadrid.com
- Site Name
- University Hospital Virgen Del Rocio S.L.
- Department Name
- Oncology
- Contact Person Name
- Alejandro Falcón González
- Contact Person Email
- afalconglez@gmail.com
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Oncology
- Contact Person Name
- Antonio Gonzalez Martin
- Contact Person Email
- aginzalezma@unav.es
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Oncology
- Contact Person Name
- Guillermo Antonio De Velasco Oria de Rueda
- Contact Person Email
- Gdevelasco.gdv@gmail.com
- Site Name
- Fundacion Rioja Salud
- Department Name
- Oncology
- Contact Person Name
- Maria De Miguel
- Contact Person Email
- maria.demiguel@startrioja.com
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Oncology
- Contact Person Name
- Antonio Gonzalez Martin
- Contact Person Email
- aginzalezma@unav.es
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncology
- Contact Person Name
- Victoria Sanchez Perez
- Contact Person Email
- victoriasanchez@vhio.net
France
- Earliest CTIS Part Ii Submission Date
- 27-04-2025
- Latest Decision Or Authorization Date
- 12-05-2026
- Processing Time Days
- 380
- Number Of Sites
- 2
- Number Of Participants
- 8
Sites
- Site Name
- Institut Godinot
- Department Name
- Oncologie médicale
- Contact Person Name
- Camille Mazza
- Contact Person Email
- camille.mazza@reims.unicancer.fr
- Site Name
- Institut Bergonie
- Department Name
- Oncologie médicale
- Contact Person Name
- Diego Teyssonneau
- Contact Person Email
- d.teyssonneau@bordeaux.unicancer.fr
Hungary
- Earliest CTIS Part Ii Submission Date
- 05-01-2026
- Latest Decision Or Authorization Date
- 15-05-2026
- Processing Time Days
- 130
- Number Of Sites
- 1
- Number Of Participants
- 5
Sites
- Site Name
- Orszagos Onkologiai Intezet
- Department Name
- Chemotherapy "B"
- Contact Person Name
- Gabor Rubovszky
- Contact Person Email
- rubovszky.gabor@oncol.hu
Poland
- Earliest CTIS Part Ii Submission Date
- 02-02-2026
- Latest Decision Or Authorization Date
- 15-05-2026
- Processing Time Days
- 102
- Number Of Sites
- 5
- Number Of Participants
- 28
Sites
- Site Name
- Uniwersytecki Szpital Kliniczny W Poznaniu
- Department Name
- Oncology
- Contact Person Name
- Rodryg Ramlau
- Contact Person Email
- rramlau@gmail.com
- Site Name
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A.
- Department Name
- Oncology
- Contact Person Name
- Wioletta Laszczewska
- Contact Person Email
- w.laszczewska@ctw.com.pl
- Site Name
- Uniwersyteckie Centrum Kliniczne
- Department Name
- Oncology Clinic
- Contact Person Name
- Katarzyna Szymczak
- Contact Person Email
- kszymczak@uck.gda.pl
- Site Name
- Instytut Centrum Zdrowia Matki Polki
- Department Name
- Oncology Clinic
- Contact Person Name
- Ewa Kalinka
- Contact Person Email
- ewakalinka@wp.pl
- Site Name
- Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
- Department Name
- Early Phase Trial Unit
- Contact Person Name
- Katarzyna Kozak
- Contact Person Email
- katarzyna.kozak@nio.gov.pl
Sponsor
Primary sponsor
- Full Name
- Duke Street Bio Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- DSB2455
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)